Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced Phase IIb data for MK-3102, the company's
investigational once-weekly DPP-4 inhibitor in development for the
treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar
in this 12-week study compared with placebo, with an incidence of
symptomatic hypoglycemia that was similar to placebo, in patients with
type 2 diabetes. These data were presented today at the 48th
Annual Meeting of the European Association for the Study of Diabetes
(EASD) in Berlin.
"If approved, MK-3102 would provide a novel, once-weekly treatment
option to help reduce blood sugar levels in patients with type 2
diabetes," said lead study author Ira Gantz, M.D., Clinical Research,
Metabolism, Merck Research Laboratories.
Can fasting improve diabetes outcomes? Ramadan offers insights